References
- Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710–17.
- Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of Gastrointestinal Disease in the United States: 2012 Update. Gastroenterology 2012;143:1179–87; e3.
- Toghanian S, Wahlqvist P, Johnson DA, Bolge SC, Liljas B. The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts. Clin Drug Investig 2010;30:167–78.
- Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway. Norwegian J Epidemiol 2008;18:129–36.
- Reimer C, Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients. Aliment Pharmacol Ther 2009;30:725–32.
- Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut 2012;61:1390–7.
- Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk JG, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119–24.
- Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927–35.
- Metz DC, Pilmer BL, Han C, Perez MC. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Astroenterol 2011;106:1953–60.
- Gerson LB, Bonafede M, Princic N, Gregory C, Farr A, Balu S. Development of a refractory gastro-oesophageal reflux score using an administrative claims database. Aliment Pharmacol Ther 2011;34:555–67.
- Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616–20.
- Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80–7; 87 e1.
- Gerson LB, Hatton BN, Ryono R, Jones W, Pulliam G, Sampliner RE, et al. Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:397–406.
- Raisch DW, Klaurens LM, Hayden C, Malagon I, Pulliam G, Fass R. Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms. Dig Dis Sci 2001;46:1533–9.
- Skinner BJ, Gray JR, Attara GP. Increased health costs from mandated Therapeutic Substitution of proton pump inhibitors in British Columbia. Aliment Pharmacol Ther 2009;29:882–91.
- Alemayehu B, Ke X, Youssef NN, Crawley JA, Levine DS. Esomeprazole formulary exclusion: impact on total health care services use and costs. Postgrad Med 2012;124:149–63.